Induction of tumor immunity by autologous B lymphoma cells expressing a genetically engineered idiotype

被引:12
作者
Selmayr, M
Strehl, J
Kremer, JP
Kremmer, E
Doenecke, A
Hallek, M
Menzel, H
Thielemans, K
Thierfelder, S
Mocikat, R
机构
[1] GSF, Inst Mol Immunol, D-81377 Munich, Germany
[2] GSF, Inst Expt Hamatol, D-81377 Munich, Germany
[3] GSF, Klin Hamatol, D-81377 Munich, Germany
[4] Univ Munich, Genzentrum, Munich, Germany
[5] Free Univ Brussels, Sch Med, Physiol Lab, Brussels, Belgium
关键词
gene therapy; GM-CSF; homologous recombination; B cell lymphoma;
D O I
10.1038/sj.gt.3300875
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A fusion protein containing a B cell lymphoma idiotype (Id) and granulocyte-macrophage colony-stimulating factor (GIW-CSF) is a potent stimulator of tumor immunity. In three different tumor models we show that immunization with autologous lymphoma cells that have been engineered to express the Id in the context of GlW-CSF is much more effective than immunization with an equivalent dose of the purified protein. The lymphoma Id could be modified by I introducing the GM-CSF gene into the immunoglobulin (Ig) heavy chain locus via gene targeting. This approach circumvents the isolation of the rearranged immunoglobulin variable genes from the tumor and the preparation of tumor-specific vector constructs. The low production of Id/GM-CSF fusion proteins by transfected cells, which is a major obstacle in the use of purified fusion proteins for immunotherapy, is due to the presence of the cytokine gene in the immunoglobulin locus. Low production, however, is not limiting in the cell-based setting, because upon in vivo administration of the modified autologous cells, even minute expression levels are sufficient to induce tumor immunity.
引用
收藏
页码:778 / 784
页数:7
相关论文
共 37 条
  • [1] CHARACTERIZATION OF A CARCINOGEN-INDUCED MURINE B-LYMPHOCYTE CELL LINE OF C3H-EB ORIGIN
    BERGMAN, Y
    HAIMOVICH, J
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 1977, 7 (07) : 413 - 417
  • [2] Human tumor antigens recognized by T lymphocytes
    Boon, T
    vanderBruggen, P
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (03) : 725 - 729
  • [3] BORDEN EC, 1990, CANCER, V65, P800, DOI 10.1002/1097-0142(19900201)65:3+<800::AID-CNCR2820651328>3.0.CO
  • [4] 2-Y
  • [5] BROWN SL, 1989, SEMIN ONCOL, V16, P199
  • [6] CAMPBELL MJ, 1990, J IMMUNOL, V145, P1029
  • [7] CAMPBELL MJ, 1987, J IMMUNOL, V139, P2825
  • [8] CHACE JH, 1994, J IMMUNOL, V152, P405
  • [9] COSTIMULATION OF ANTITUMOR IMMUNITY BY THE B7 COUNTERRECEPTOR FOR THE LYMPHOCYTE-T MOLECULES CD28 AND CTLA-4
    CHEN, LP
    ASHE, S
    BRADY, WA
    HELLSTROM, I
    HELLSTROM, KE
    LEDBETTER, JA
    MCGOWAN, P
    LINSLEY, PS
    [J]. CELL, 1992, 71 (07) : 1093 - 1102
  • [10] CYTOKINE GENE-TRANSFER IN TUMOR-INHIBITION AND TUMOR-THERAPY - WHERE ARE WE NOW
    COLOMBO, MP
    FORNI, G
    [J]. IMMUNOLOGY TODAY, 1994, 15 (02): : 48 - 51